@article{article, title  = {{Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal}},

 publisher = {{Springer Verlag}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/106724 http://dx.doi.org/10.1007/s40273-016-0436-6 }},

 year = {{2016}},

 month = {{8}},

 author = {{Rafia R and Scope A and Harnan S and Stevens JW and Stevenson M and Lobo A}},

 doi = {{10.1007/s40273-016-0436-6}},

 journal = {{PharmacoEconomics}},

 note = {{Accessed on 2025/11/05}}}